Inflammation therapeutic biosimilar - Zydus Cadila

Drug Profile

Inflammation therapeutic biosimilar - Zydus Cadila

Alternative Names: Prod 3

Latest Information Update: 22 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zydus Cadila
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Myocardial infarction
  • Research Inflammation

Most Recent Events

  • 22 Oct 2015 Early research in Inflammation in India (unspecified route) before October 2015 (Zydus pipeline, October 2015)
  • 22 Oct 2015 Preclinical trials in Myocardial infarction in India (Parenteral) (Zydus presentation, May 2015)
  • 28 Feb 2014 Early research in Myocardial infarction in India (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top